Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 11:2021:8849039.
doi: 10.1155/2021/8849039. eCollection 2021.

Survival Analysis of Radiation Therapy in Ovarian Cancer: A SEER Database Analysis

Lushi Yu  1 , Hongyun Gong  1 , Qian Li  1 , Honggang Ren  1 , Yi Wang  1 , Haihua He  1 , Tian Li  2 , Qibin Song  1
Affiliations

Survival Analysis of Radiation Therapy in Ovarian Cancer: A SEER Database Analysis

Lushi Yu et al. J Oncol. .

Abstract

Results: A total of 20031 ovarian cancer patients were included, with 291 (1.45%) patients who received radiotherapy. The median overall survival (OS) in patients who received radiotherapy was shorter than which in patients without radiotherapy (23 vs. 75 months, P < 0.001). The Elderly, nonepithelial pathology, advanced American Joint Committee on Cancer (AJCC) stage, elevated level of CA125, and receiving radiotherapy were risk predictors to survival in both multivariable analyses before and after PSM. Among 11872 patients with III/IV stage, the radiotherapy group also showed a significantly worse prognosis (median OS: 19 vs. 44 months in patients without radiotherapy, P < 0.001). Consistent results were observed in stratification analyses on pathology and stage among patients with III/IV stage.

Conclusions: For patients with ovarian cancer, radiotherapy was associated with a poor prognosis regardless of pathology or stage. Considering this is a retrospective study, future studies concerning radiotherapy combination with other new agents in ovarian cancer are needed.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest regarding the publication of this article.

Figures

Figure 1
Figure 1
Overall survival and cause specific survival among ovarian cancer patients with or without radiotherapy. RT: radiotherapy; OS: overall survival; CSS: cause specific survival; NR: not reached.
Figure 2
Figure 2
Multivariate survival analysis among ovarian cancer patients. HR: hazard ratio; CI: confidence interval; Ref.: reference; UNK: unknown; R: radiotherapy; S: surgery; C:;chemotherapy.
Figure 3
Figure 3
Overall survival and cause specific survival for radiotherapy among ovarian cancer patients with III/IV stage. OS and CSS for RT and non-RT among ovarian cancer patients with III/IV stage are shown in (a) and (b), respectively; patients with RT were further divided into four groups according the therapies combined with RT, and the OS and CSS are shown in (c) and (d). RT: radiotherapy; R: radiotherapy; S: surgery; C: chemotherapy; OS: overall survival; CSS: cause specific survival.
Figure 4
Figure 4
Stratified survival analyses by radiotherapy among ovarian cancer patients with III/IV stage. (a). (b). Kaplan–Meier curves for overall survival in stratification analysis according to pathological type. (c). (d). Kaplan–Meier curves for overall survival in stratification analysis according to stage. RT: radiotherapy.
See this image and copyright information in PMC

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394–424. doi: 10.3322/caac.21492<remarks>Doi_inserted_from_Crossref</remarks>. - DOI - PubMed
    1. Lheureux S., Braunstein M., Oza A. M. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA: A Cancer Journal for Clinicians. 2019;69:280–304. doi: 10.3322/caac.21559. - DOI - PubMed
    1. Torre L. A., Trabert B., DeSantis C. E., et al. Ovarian cancer statistics, 2018. CA: A Cancer Journal for Clinicians. 2018;68(4):284–296. doi: 10.3322/caac.21456<remarks>Doi_inserted_from_Crossref</remarks>. - DOI - PMC - PubMed
    1. Harter P., Bois A. d., Hahmann M., et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Annals of Surgical Oncology. 2006;13(12):1702–1710. doi: 10.1245/s10434-006-9058-0<remarks>Doi_inserted_from_Crossref</remarks>. - DOI - PubMed
    1. Kehoe S., Hook J., Nankivell M., et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. The Lancet. 2015;386(9990):249–257. doi: 10.1016/s0140-6736(14)62223-6<remarks>Doi_inserted_from_Crossref</remarks>. - DOI - PubMed

LinkOut - more resources